TW202615041A - 口服膠囊劑及其製備方法 - Google Patents

口服膠囊劑及其製備方法

Info

Publication number
TW202615041A
TW202615041A TW114149446A TW114149446A TW202615041A TW 202615041 A TW202615041 A TW 202615041A TW 114149446 A TW114149446 A TW 114149446A TW 114149446 A TW114149446 A TW 114149446A TW 202615041 A TW202615041 A TW 202615041A
Authority
TW
Taiwan
Prior art keywords
oral capsule
zanubrutinib
oral
capsule
rpm
Prior art date
Application number
TW114149446A
Other languages
English (en)
Chinese (zh)
Inventor
王亦平
郭遠靜
Original Assignee
瑞士商百濟神州瑞士有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商百濟神州瑞士有限責任公司 filed Critical 瑞士商百濟神州瑞士有限責任公司
Publication of TW202615041A publication Critical patent/TW202615041A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW114149446A 2019-06-10 2020-06-10 口服膠囊劑及其製備方法 TW202615041A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090543 2019-06-10
WOPCT/CN2019/090543 2019-06-10

Publications (1)

Publication Number Publication Date
TW202615041A true TW202615041A (zh) 2026-04-16

Family

ID=73780902

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114149446A TW202615041A (zh) 2019-06-10 2020-06-10 口服膠囊劑及其製備方法
TW109119516A TW202112369A (zh) 2019-06-10 2020-06-10 口服膠囊劑及其製備方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109119516A TW202112369A (zh) 2019-06-10 2020-06-10 口服膠囊劑及其製備方法

Country Status (6)

Country Link
US (2) US20220241285A1 (enExample)
EP (1) EP3981400A4 (enExample)
JP (2) JP2022538215A (enExample)
CN (1) CN113950327A (enExample)
TW (2) TW202615041A (enExample)
WO (1) WO2020249002A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
IL293319B1 (en) 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
CN115212115A (zh) * 2021-09-27 2022-10-21 百济神州(苏州)生物科技有限公司 泽布替尼的鼻饲给药
CN119699478B (zh) * 2024-12-24 2025-12-12 衡睿(广东)生物科技有限公司 一种高油脂含量的胶囊制剂及其制备方法
CN119818691B (zh) * 2025-03-18 2025-08-05 宁波美诺华天康药业有限公司 一种含有伊布替尼的药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2989106T3 (pl) * 2013-04-25 2017-08-31 Beigene, Ltd. Połączone związki heterocykliczne jako inhibitory kinazy białkowej
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL293319B1 (en) * 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
CN112165939A (zh) * 2018-03-21 2021-01-01 梅制药公司 联合疗法
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Also Published As

Publication number Publication date
US20220241285A1 (en) 2022-08-04
JP2022538215A (ja) 2022-09-01
WO2020249002A1 (zh) 2020-12-17
TW202112369A (zh) 2021-04-01
US20230149411A1 (en) 2023-05-18
EP3981400A1 (en) 2022-04-13
JP2025123534A (ja) 2025-08-22
CN113950327A (zh) 2022-01-18
EP3981400A4 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
JP2025123534A (ja) 経口カプセルおよびその調製方法
JP7258924B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US12233069B2 (en) Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor
CN112220770B (zh) 司来帕格的药物组合物及其制备方法
WO2014104671A1 (ko) 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
JP2023549763A (ja) 複素環式化合物を含む組成物、その製造方法と応用
CN110621662A (zh) 一种盐的结晶性固体形式、制备工艺和使用方法
JP2019142927A (ja) 医薬剤形
TW201840320A (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
KR20030024833A (ko) 시탈로프람을 함유하는 약학 조성물
JP2023548855A (ja) キナーゼ阻害剤の医薬組成物
CN108938586B (zh) 一种含有喹啉衍生物或其盐的药物组合物的制备方法
CN121038782A (zh) 具有改善的生物利用度的仑伐替尼组合物
CN112057432A (zh) 口服胶囊剂及其制备方法
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
HK40066903A (en) Oral capsule and preparation method therefor
CN112057427A (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
JP2007186450A (ja) 塩酸パロキセチン含有製剤およびその製造方法
HK40062459A (en) Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN117919186A (zh) 一种甲磺酸沙芬酰胺片及其制备方法
JP2011241181A (ja) クエチアピンフマル酸塩含有経口用錠剤
KR20210049583A (ko) 생산성 및 용출성이 개선된 소라페닙 토실레이트염의 제제 및 그 제조 방법
KR20200050398A (ko) 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법